OPKO Health, Inc. (NASDAQ:OPK) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 11.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 776,020 shares of the biotechnology company’s stock after purchasing an additional 79,525 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.11% of OPKO Health worth $931,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Invesco Ltd. lifted its stake in OPKO Health by 300.4% during the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock worth $8,263,000 after purchasing an additional 3,874,519 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of OPKO Health by 19.3% during the 4th quarter. SG Americas Securities LLC now owns 244,294 shares of the biotechnology company’s stock worth $369,000 after buying an additional 39,459 shares during the last quarter. Moseley Investment Management Inc. acquired a new position in shares of OPKO Health in the 1st quarter valued at $41,000. EP Wealth Advisors LLC grew its position in shares of OPKO Health by 140.3% in the 3rd quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 18,041 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in OPKO Health by 349.8% during the 4th quarter. BNP Paribas Financial Markets now owns 271,872 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 211,429 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Trading Down 1.6 %

Shares of OPK stock opened at $1.23 on Tuesday. OPKO Health, Inc. has a twelve month low of $0.85 and a twelve month high of $2.24. The company has a market capitalization of $857.30 million, a price-to-earnings ratio of -3.51 and a beta of 1.65. The firm has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.19. The company has a current ratio of 1.91, a quick ratio of 1.62 and a debt-to-equity ratio of 0.27.

OPKO Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The business had revenue of $173.70 million for the quarter, compared to analysts’ expectations of $182.99 million. OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The business’s quarterly revenue was down 26.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.02) earnings per share. Research analysts forecast that OPKO Health, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was purchased at an average price of $1.27 per share, for a total transaction of $127,000.00. Following the acquisition, the chief executive officer now directly owns 211,232,222 shares in the company, valued at $268,264,921.94. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 47.26% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OPK. StockNews.com raised OPKO Health to a “sell” rating in a research report on Tuesday, June 4th. Barrington Research reiterated an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, May 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 target price on shares of OPKO Health in a report on Monday, April 1st.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.